Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
  Report
Delayed Nasdaq Copenhagen  -  03:00 2022-09-27 am EDT
35.00 DKK   +3.24%
09/27Virogates A/s : SuPAR associates with mortality and improves risk stratification independently of other previously known risk factors in CS patients.
PU
09/23ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform
AQ
09/23ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform
CI
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates A/S : SuPAR as a Prognostic Marker of Ugandan Children at Risk of Severe and Fatal Malaria

06/15/2022 | 06:13am EDT

Background

Current malaria diagnostic tests do not reliably identify children at risk of severe and fatal infection. Host immune and endothelial activation contribute to malaria pathogenesis. Soluble urokinase-type plasminogen activator receptor (suPAR) is a marker of these pathways. We hypothesized that measuring suPAR at presentation could risk-stratify children with malaria.

Methods

Plasma suPAR levels were determined in consecutive febrile children with malaria at presentation to hospital in Jinja, Uganda. We evaluated the accuracy of suPAR in predicting in-hospital mortality, and whether suPAR could improve a validated clinical scoring system (Lambaréné Organ Dysfunction Score; LODS).

Results
Of the 1226 children with malaria, 39 (3.2%) died. suPAR concentrations at presentation were significantly higher in children who went on to die than in those who survived (P < .0001). suPAR levels were associated with disease severity (LODS 0 v. 1, P = .001; LODS 1 vs. 2, P < .001; LODS 2 vs. 3, LODS 0 vs. 2, LODS 1 vs. 3, and LODS 0 v. 3; P < .0001). suPAR concentrations were excellent predictors of in-hospital mortality (AUROC, 0.92 [95% CI, 0.91-0.94]). The prognostic accuracy of LODS (AUROC, 0.93 [95% CI, 0.91-0.94]) was improved when suPAR was added (AUROC, 0.97 [95% CI, 0.96-0.98]; P < .0001).

Conclusions

Measuring suPAR at presentation can identify children at risk of severe and fatal malaria. Adding suPAR to clinical scores could improve the recognition and triage of children at risk of death. suPAR can be detected with a point-of-care test and can now be evaluated in prospective trials.

Disclaimer

ViroGates A/S published this content on 14 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 June 2022 10:12:08 UTC.


© Publicnow 2022
All news about VIROGATES A/S
09/27Virogates A/s : SuPAR associates with mortality and improves risk stratification independe..
PU
09/23ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter ..
AQ
09/23ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter ..
CI
09/22Virogates A/s : SuPAR predicts kidney function decline in patients presenting in the Emerg..
PU
09/06Virogates A/s : SuPAR levels correlate with disease severity and survival rate of COVID-19..
PU
08/18Virogates A/s : Half-Year Report, H1 2022
PU
08/18Virogates Announces Its Half-year Re : 62% revenue growth and new EBIT guidance
AQ
08/18ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/15Virogates A/s : Higher suPAR is associated with incident venous thromboembolism independen..
PU
07/15ViroGates notification of transactions by persons discharging managerial responsibiliti..
AQ
More news
Financials
Sales 2021 7,66 M 0,99 M 0,99 M
Net income 2021 -17,7 M -2,28 M -2,28 M
Net cash 2021 14,9 M 1,92 M 1,92 M
P/E ratio 2021 -25,7x
Yield 2021 -
Capitalization 117 M 15,1 M 15,1 M
EV / Sales 2020 41,3x
EV / Sales 2021 57,6x
Nbr of Employees 12
Free-Float 50,4%
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
Patrik Olof Dahlén Independent Director
Sector and Competitors